• Interstitial Lung Disease Diagnoses Usually Inaccurate, Emotionally Trying, Patient Survey Shows
  • Pulmonary Fibrosis Foundation Expands National Care Center Network
  • Eiger BioPharmaceuticals Discontinues Development of Ubenimex in PAH After Disappointing Results
  • FDA Advisory Committee Does Not Recommend Approval of Inhalant Linhaliq
  • Health Canada Issues Safety Warning on Pulmonary Fibrosis Therapy Ofev
  • Fasenra Approved in EU for Treatment of Severe Eosinophilic Asthma
  • Owlstone Medical Among Finalists in IPF Catalyst Challenge
  • European Union Approves Orkambi Use for Children 6-11 Years Old
  • Bellerophon Enrolls First Patient in Study of INOpulse to Treat PH Linked to Interstitial Lung Disease
  • Insurance Coverage Affects Treatment Given Small-cell Lung Cancer Patients in US, Study Shows
  • Proteostasis’ Planned Trial of Triple Combo CF Therapy Supported By Advocacy Groups in US, Europe
  • Tackling Asthma’s Genetic Causes May Yield New Therapies and ID Higher-risk Patients, Yale Study Says

Pulmonary Fibrosis

Asthma

Bronchiectasis

BRONCHIOLITIS

CHRONIC BRONCHITIS

COPD

 CYSTIC FIBROSIS

EMPHYSEMA

IDIOPATHIC PULMONARY FIBROSIS

LUNG CANCER

PNEUMONIA

PULMONARY HYPERTENSION

SCLERODERMA